Matches in Nanopublications for { ?s ?p "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1293554.RASotFYvst3D0NJ4WXSC5tKfIEQf4cfbz_19AOS3mngmE130_assertion description "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293554.RASotFYvst3D0NJ4WXSC5tKfIEQf4cfbz_19AOS3mngmE130_provenance.
- NP1293552.RAAw4Qje6mL8JKRVDxRSO3tfwS6YTKvhBodKpxNE2RzQY130_assertion description "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293552.RAAw4Qje6mL8JKRVDxRSO3tfwS6YTKvhBodKpxNE2RzQY130_provenance.
- NP1293557.RA7GDeMdvblOd220F5eyTpmFRLCtiGK2Fvfcjd9Zr0gC8130_assertion description "[To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-? inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-?M51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293557.RA7GDeMdvblOd220F5eyTpmFRLCtiGK2Fvfcjd9Zr0gC8130_provenance.